# Ralf Gutzmer

Source: https://onco.cc/people/ralf-gutzmer/  
OnCo record `ralf-gutzmer` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

German dermato-oncologist who was lead author of IMspire150, the trial that added atezolizumab to vemurafenib and cobimetinib in BRAF-mutant melanoma.

## Summary

Ralf Gutzmer is a German dermato-oncologist who led skin cancer research at Hannover Medical School before moving to the Mühlenkreiskliniken in Minden. He was first author of the 2020 Lancet report of IMspire150, the phase 3 trial in which atezolizumab plus vemurafenib and cobimetinib lengthened progression-free survival compared with the two targeted drugs alone in untreated BRAF V600-mutant advanced melanoma, the first approval of a triplet combining immunotherapy and BRAF-MEK inhibition.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: melanoma; immunotherapy; trialist
- Role: Dermato-oncologist and trial lead
- Specialisms: Melanoma; Targeted plus immunotherapy combinations; Dermato-oncology

## Connected records

- cancers: [BRAF V600-mutant melanoma](https://onco.cc/cancers/braf-v600-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- trials: [IMspire150](https://onco.cc/trials/imspire150/)

---
JSON: https://onco.cc/api/v1/entities/ralf-gutzmer.json